Mason Street Advisors LLC bought a new position in shares of Hologic Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 32,675 shares of the company’s stock, valued at approximately $1,131,000.
Other large investors have also modified their holdings of the company. Chevy Chase Trust Holdings Inc. acquired a new stake in shares of Hologic during the first quarter worth $7,209,000. Exxonmobil Investment Management Inc. TX purchased a new stake in Hologic during the first quarter valued at $2,074,000. Glenmede Trust Co. NA increased its stake in Hologic by 259.8% in the first quarter. Glenmede Trust Co. NA now owns 18,710 shares of the company’s stock valued at $644,000 after buying an additional 13,510 shares during the period. Commonwealth Equity Services Inc increased its stake in Hologic by 13.5% in the first quarter. Commonwealth Equity Services Inc now owns 63,633 shares of the company’s stock valued at $2,195,000 after buying an additional 7,585 shares during the period. Finally, Virginia Retirement System purchased a new stake in Hologic during the first quarter valued at $14,014,000. 94.51% of the stock is currently owned by hedge funds and other institutional investors.
Hologic Inc. (NASDAQ:HOLX) opened at 38.45 on Monday. The firm has a market cap of $10.67 billion, a P/E ratio of 42.39 and a beta of 1.03. The firm’s 50-day moving average price is $38.35 and its 200-day moving average price is $35.91. Hologic Inc. has a 1-year low of $31.84 and a 1-year high of $41.66.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The business earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. During the same period in the prior year, the business posted $0.43 earnings per share. The company’s revenue was up 3.4% on a year-over-year basis. Equities research analysts anticipate that Hologic Inc. will post $1.94 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on HOLX shares. Bank of America Corp. reissued a “buy” rating on shares of Hologic in a report on Wednesday, June 22nd. Leerink Swann reissued a “buy” rating and set a $46.00 price objective on shares of Hologic in a report on Thursday, July 28th. Canaccord Genuity set a $45.00 price objective on Hologic and gave the company a “buy” rating in a report on Thursday, July 28th. Jefferies Group raised their price objective on Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Finally, RBC Capital Markets reissued a “sector perform” rating and set a $39.00 price objective (up previously from $37.00) on shares of Hologic in a report on Monday, August 1st. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $42.47.
In other news, Director Nancy Leaming sold 8,179 shares of the company’s stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $37.00, for a total transaction of $302,623.00. Following the completion of the transaction, the director now directly owns 67,140 shares of the company’s stock, valued at $2,484,180. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.84% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.